Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14955176 | 1.00 | ALDH1A1 (0.61) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL31483213 | 0.83 | MAPT (0.50) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL4159119 | 0.83 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20452073 | 0.83 | ALDH1A1 (0.58) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL4800670 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL18453943 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20452440 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL15525147 | 0.81 | ALDH1A1 (0.59) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL18453947 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A | |
| SCHEMBL20452151 | 0.81 | ALDH1A1 (0.56) | ALDH1A1RAB9ASMN1; SMN2NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| EP-1567522-B1 | PYRIMIDINE COMPOUNDS | CYCLACEL LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| US-6699854-B2 | 2-SUBSTITUTED 4-HETEROARYL- PYRIMIDINES, INHIBITORS OF CYCLIN-DEPENDENT KINASES (CDKS) | CYCLACEL LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | ALDH1A1 3103/4885RAB9A 2461/4885SMN1; SMN2 4448/4885 |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | ALDH1A1 2743/4885RAB9A 2128/4885SMN1; SMN2 2335/4885 |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | ALDH1A1 2719/4885RAB9A 4076/4885SMN1; SMN2 2905/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | ALDH1A1 3103/4885RAB9A 2461/4885SMN1; SMN2 4448/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | ALDH1A1 1400/4885RAB9A 1518/4885SMN1; SMN2 1076/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | ALDH1A1 1400/4885RAB9A 1518/4885SMN1; SMN2 1076/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | ALDH1A1 2858/4885RAB9A 4034/4885SMN1; SMN2 3007/4885 |
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | ALDH1A1 2334/4885RAB9A 3043/4885SMN1; SMN2 2791/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | ALDH1A1 2334/4885RAB9A 3043/4885SMN1; SMN2 2791/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | ALDH1A1 2550/4885RAB9A 1648/4885SMN1; SMN2 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.